Roche's Avastin Fails in Pancreatic Cancer Trial

Swiss drugmaker Roche Holding Tuesday said a new late-stage study showed that the addition of Avastin to a combination of Tarceva and chemotherapy failed to prolong the lives of patients with advanced pancreatic cancer, but did have some benefits.
Marketwatch